| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11666576 | CMP DEV LLC | Liquid oral formulations for tadalafil |
Dec, 2038
(15 years from now) | |
| US11382917 | CMP DEV LLC | Liquid oral formulations for tadalafil |
Dec, 2038
(15 years from now) | |
Tadliq is owned by Cmp Dev Llc.
Tadliq contains Tadalafil.
Tadliq has a total of 2 drug patents out of which 0 drug patents have expired.
Tadliq was authorised for market use on 17 June, 2022.
Tadliq is available in suspension;oral dosage forms.
Tadliq can be used as tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability.
The generics of Tadliq are possible to be released after 24 December, 2038.
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 17 June, 2022
Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability
Dosage: SUSPENSION;ORAL
TADLIQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic